The U.S. Food and Drug Administration has approved daraxonrasib, a new treatment for adults with metastatic pancreatic adenocarcinoma. This approval is for patients who have already received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. Daraxonrasib is an oral multi-selective RAS(ON) inhibitor, marking a significant advancement in the treatment environment for this aggressive cancer.
The decision is based on the RASolute 302 trial, a phase 3 study led by Brian Wolpin, MD, MPH, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute. The trial compared daraxonrasib to chemotherapy as a second-line therapy for patients with metastatic pancreatic cancer. Wolpin emphasized the historical challenge of targeting RAS, noting that this approval represents a breakthrough after years of research.
A Landmark Advance in Pancreatic Cancer Treatment
Daraxonrasib is the first approved targeted therapy in pancreatic cancer designed to inhibit RAS, a major cancer-driving pathway. It acts as a molecular glue, blocking RAS protein signaling when combined with another protein, cyclophilin A.
The RASolute 302 study, presented at the 2026 American Society of Clinical Oncology meeting and published in the New England Journal of Medicine, enrolled 500 patients across North America, Europe, and Asia. All participants had previously undergone one line of chemotherapy for metastatic disease.
Significant Improvement in Survival Rates
Patients treated with daraxonrasib showed a 60% reduced risk of death compared to those on chemotherapy, with a hazard ratio of 0.40. The median overall survival was 13.2 months with daraxonrasib, versus 6.7 months with chemotherapy. Progression-free survival also improved significantly, with a median of 7.2 months compared to 3.6 months.
The objective response rate was 31.6% with daraxonrasib, compared to 11.2% with chemotherapy. Among patients with a known RAS G12 mutation, 33.2% experienced substantial tumor shrinkage or disappearance with daraxonrasib, versus 11.8% on chemotherapy.
Read Also: Diabetes drugs may cause hair loss risk
For patients and families, this approval offers a long-awaited advance. It demonstrates how studying cancer biology can lead to new treatments, even for difficult-to-treat cancers. The future now holds promise, as researchers build on this approval to identify further approaches that provide durable disease responses and more cures. Wolpin described this moment as the beginning of a new era in pancreatic cancer treatment, with daraxonrasib serving as a foundation for future innovations.
Safety Profile and Side Effects
No new safety concerns were identified with daraxonrasib compared to earlier trial data. The most common side effects included rash, mouth inflammation, nausea, and diarrhea.
Pancreatic ductal adenocarcinoma remains one of the deadliest cancers, with approximately 65,000 new cases and 50,000 deaths annually in the United States. Early detection is rare, as symptoms often appear only after the cancer has spread. The five-year survival rate for metastatic cases is approximately 3%.
A Milestone in Cancer Research
Benjamin L. Ebert, MD, PhD, president and CEO of Dana-Farber, emphasized the significance of this approval. He noted that it reflects the power of sustained investment in scientific discovery and clinical research. Dana-Farber remains committed to developing the next generation of treatments for pancreatic cancer, building on the success of daraxonrasib.
Wolpin expressed optimism about the future of pancreatic cancer treatment. He highlighted how the approval of daraxonrasib marks the beginning of a new era, with ongoing research focused on identifying further approaches to provide durable disease responses and more cures. The Hale Center team and the broader field are poised to leverage this breakthrough to explore additional therapeutic strategies.
